WO2023104181A1 - Composition hypoglycémiante - Google Patents

Composition hypoglycémiante Download PDF

Info

Publication number
WO2023104181A1
WO2023104181A1 PCT/CN2022/137829 CN2022137829W WO2023104181A1 WO 2023104181 A1 WO2023104181 A1 WO 2023104181A1 CN 2022137829 W CN2022137829 W CN 2022137829W WO 2023104181 A1 WO2023104181 A1 WO 2023104181A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucan
composition
phytosterol
phytosterols
yeast
Prior art date
Application number
PCT/CN2022/137829
Other languages
English (en)
Chinese (zh)
Inventor
崔东影
解庆刚
刘莹
陆思宇
蒋士龙
梁爱梅
张永久
蔡方良
冷友斌
Original Assignee
黑龙江飞鹤乳业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 黑龙江飞鹤乳业有限公司 filed Critical 黑龙江飞鹤乳业有限公司
Publication of WO2023104181A1 publication Critical patent/WO2023104181A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/181—Sugars or sugar alcohols
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/36—Vegetable material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the field of food, and relates to a functional nutritional composition, more specifically, to a functional health care or nutritional composition with hypoglycemic effect.
  • three highs refers to hypertension, hyperglycemia (diabetes) and hyperlipidemia. They belong to cardiovascular and cerebrovascular diseases. They are mainly "diseases of wealth” derived from modern civilization. They may exist alone or may be related to each other. For example, people with diabetes are likely to suffer from high blood pressure or hyperglycemia at the same time, and high blood sugar is the main factor in the formation and development of arteriosclerosis. Patients with arteriosclerosis have poor blood vessel elasticity, which will aggravate the increase in blood pressure. Therefore, any one of these three diseases will easily develop into "three highs" in the later stage, especially among the elderly and those with declining body functions.
  • diabetes Globally, the number of people suffering from diabetes is increasing every year, and there is no obvious effective treatment. The incidence of diabetes also increases with age, and middle-aged and elderly diabetic patients account for 98% of the total number of diabetic patients. Moreover, diabetes can also cause a variety of complications. Diabetes and its complications will bring physical and mental damage to the patient, and even threaten the life and health of the patient. At the same time, it will also bring human and material losses to the patient's family. . Therefore, preventing the occurrence of diabetes and reducing the harm of diabetes is an urgent problem in our society today. In today's society, diet control, oral hypoglycemic drugs, and insulin injections are often used to control blood sugar. This not only limits the diversity of nutritional components in food consumed by patients, but also brings various pains and inconveniences to patients. Therefore, it is particularly important to develop a healthy and hypoglycemic composition without side effects.
  • ⁇ -glucan is composed of glucose units, exists widely in microorganisms, plants and animals, and is a polysaccharide unit of glucose. Structurally, most of them are combined by ⁇ -1,3 bonds, which is a kind of polymer with certain biological activity.
  • ⁇ -1,3 bonds which is a kind of polymer with certain biological activity.
  • foreign researchers discovered that there is a substance that enhances immune function on the cell wall of yeast, and it was determined that this active substance is ⁇ -1,3-glucan more than 20 years later.
  • a number of experimental studies in recent years have shown that ⁇ -glucan has a significant effect on lowering blood sugar, reducing fat and improving immunity, and is of great benefit to various physiological functions of the human body.
  • yeast glucan is derived from Saccharomyces cerevisiae. Due to its special structure, it has a variety of physiological activities, and it has been included in GRAS (generally recognized as safe) by the FDA in the United States. ), as a food raw material, is widely used in various foods. And it is also allowed to be used in various foods in most countries.
  • yeast glucan can be decomposed by intestinal bacteria, promote gastrointestinal peristalsis, stimulate the secretion of digestive juice, and have the function of assisting digestion; it can increase intestinal peristalsis and promote defecation, thereby effectively preventing constipation; it can increase the body's Intestinal absorption of calcium, magnesium and zinc.
  • the unique ⁇ -(1 ⁇ 3) skeleton structure of yeast glucan makes it have strong immunomodulatory activity and can significantly improve human immunity.
  • Phytosterols are recommended by the guidelines and consensuses of medical associations such as China, Europe, the United States, and ESC/EAS for people with abnormal blood sugar to help lower blood sugar and prevent cardiovascular diseases.
  • the recommended dose is 2-3g/day.
  • Citation 1 discloses a health food composition, which is composed of grains rich in plant polyphenols and sterols, traditional Chinese medicine and yeast.
  • the present invention exerts a synergistic hypoglycemic effect through the comprehensive action of multiple bioactive substance groups, polyphenols, sterols, dietary fiber, proteins, polypeptides, oligopeptides, ⁇ -glucans, flavonoids, D-chiro-inositol, molting Hormones and other multi-level, multi-target, and multi-angle synergistic effects have shown excellent effects in mouse hypoglycemic experiments and clinical experiments.
  • Citation 2 discloses a hypoglycemic functional food.
  • the food includes resistant starch, tea polyphenols and dietary fiber.
  • the functional food has a significant effect on inhibiting the rapid rise of blood sugar, and has a good daily health care effect on patients with diabetes and complications.
  • Citation 3 discloses a special clinical nutritional formula for gestational diabetes, which includes protein, fat, carbohydrates, vitamins, homologous components of medicine and food, natural plant compounds and new resource foods.
  • the new resource food is selected from colostrum basic protein, ⁇ -aminobutyric acid, chitosan oligosaccharide, eucommia male flower, bamboo leaf flavone, casein phosphopeptide, oat ⁇ -glucan, yeast ⁇ -glucan , Moringa leaf, at least one of xylooligosaccharides.
  • Citation 4 discloses a hypoglycemic pharmaceutical composition and health functional food. It is made of phytosterol esters, red yeast rice, tomato red, and chromium-rich yeast, and it has been proved by experiments to have a significant hypoglycemic effect.
  • Cited Document 2 proposes that one of various vitamins, sterols, amino acids, and ⁇ -glucan can be used as an optional component, but it does not mention whether these components alone have a hypoglycemic effect.
  • Citation 3 has complex components. Although ⁇ -glucan is mentioned, it is not an essential component.
  • reference 4 mentions the use of phytosterols, it needs to be combined with other substances to lower blood sugar as a whole, and the relationship between specific synergistic components is not obvious.
  • the problem to be solved by the present invention is to provide a composition with simple composition and hypoglycemic function, in which ⁇ -glucan and phytosterol are combined in a limited amount. , can obtain a synergistic effect, and the experimental results can also show that the combination can obtain an obvious hypoglycemic effect even when the dosage of phytosterol or ⁇ -glucan is low.
  • composition provided by the present invention also has the effect of lowering blood fat.
  • the present invention firstly provides a functional composition, wherein the composition comprises:
  • the dosage ratio of the phytosterol to ⁇ -glucan is 45:1 or less.
  • composition according to [2] wherein the dosage ratio of the phytosterol to ⁇ -glucan is 0.01:1 or more.
  • composition according to [1] or [2], wherein the phytosterol is selected from 4-non-methyl sterol, 4-methyl sterol and 4,4'-dimethyl sterol one or more.
  • the present invention provides a hypoglycemic composition, wherein the composition includes the composition according to any one of [1] to [8].
  • the present invention also relates to a food with hypoglycemic and blood lipid-lowering effects, wherein the food is obtained through the composition described in any one of the above [1] to [9].
  • the present invention has the following advantages and can obtain the following technical effects:
  • hypoglycemic functional composition provided by the present invention has a simple and clear composition, which is more conducive to convenient and accurate compounding, and is also more conducive to convenient addition or preparation of various foods, especially beverage foods;
  • the amount of ⁇ -glucan and phytosterol in the composition of the present invention is within the safe dosage range, so it can be used for a long time, and is suitable for various unspecified groups of people;
  • composition of the present invention also has the effects of assisting blood fat reduction, anti-fatigue and improving immunity.
  • numerical range represented by "numerical value A - numerical value B" means the range which includes numerical value A and B of an end point.
  • room temperature used means the indoor ambient temperature of "20°C”.
  • the names of units used are the names of international standard units, and if there is no special statement, the used "%" means weight or mass percentage.
  • substantially means that the standard deviation from the theoretical model or theoretical data is within the range of 5%, preferably 3%, more preferably 1%.
  • references to “some specific/preferred embodiments”, “other specific/preferred embodiments”, “embodiments” and the like refer to specific elements described in relation to the embodiments (for example, A feature, structure, property, and/or characteristic) is included in at least one embodiment described herein, and may or may not be present in other embodiments.
  • references to “some specific/preferred embodiments”, “other specific/preferred embodiments”, “embodiments” and the like refer to specific elements described in relation to the embodiments (for example, A feature, structure, property, and/or characteristic) is included in at least one embodiment described herein, and may or may not be present in other embodiments.
  • the described elements may be combined in any suitable manner in the various embodiments.
  • a functional composition comprising i) one or more phytosterols and ii) one or more sources of beta-glucan, the composition exhibiting It has an obvious synergistic effect, so as to be able to significantly control and reduce the blood sugar content of the human body, and also has the effects of assisting in reducing blood fat, anti-fatigue, etc. and improving immunity.
  • the present invention first verified the safe dosage range of phytosterols and ⁇ -glucan from the perspective of (cell) biology, and within this range, studied the biological effects of the two separately and in the case of different dosages. Therefore, it was unexpectedly found that with the combination of specific content, phytosterol and ⁇ -glucan can produce obvious synergistic effect in reducing blood sugar in human body.
  • Phytosterols are sterols present in higher plants. In clinical trials, phytosterols have been shown to block the site of cholesterol absorption in the human gut, thus helping to reduce cholesterol levels in the body.
  • the relative density of phytosterol is slightly higher than water, insoluble in water, acid and alkali, soluble in various organic solvents, such as vegetable oil, ether, benzene, chloroform, ethyl acetate, carbon disulfide and petroleum ether.
  • organic solvents such as vegetable oil, ether, benzene, chloroform, ethyl acetate, carbon disulfide and petroleum ether.
  • the physical and chemical properties of phytosterols are mainly hydrophobic, but because of the hydroxyl group in their structure, they are also hydrophilic, so phytosterols usually have certain emulsifying properties.
  • the type of phytosterols in the present invention is not particularly limited, and may be one or more of 4-methylsterols, 4-methylsterols, and 4,4'-dimethylsterols.
  • the phytosterols suitable for the present invention can be selected from at least one of sitosterol, campesterol, stigmasterol, brassicasterol and corresponding alkanols or a mixture thereof.
  • plant foods with high phytosterol content include vegetable oils, nuts, seeds, beans, etc.
  • vegetable oils corn germ oil had the highest phytosterol content, followed by sesame oil; among nuts and seeds, pistachio had the highest content, followed by black sesame; among beans, soybeans had the highest content, followed by green beans; among vegetables, fruits and potatoes, phytosterols Alcohol content is low.
  • plant materials containing phytosterols can be used to give a certain content of phytosterols in the final composition.
  • the method of using the extracted phytosterols such sterols can be used directly to form a mixture, or the phytosterols can be prepared as a solution or emulsion before use.
  • Beta-glucan belongs to fiber polysaccharides (complex sugars). Structurally, most of them are polymers bound by ⁇ -1,3 bonds, and can be derived from a variety of Microorganisms, animals or plants.
  • the specific source of ⁇ -glucan in the present invention is not particularly limited, and the source of ⁇ -glucan applicable to the present invention includes yeast, oats, barley, fungi (mushrooms) and algae, etc. or one of them mixture. Can be further specifically listed such as oat ⁇ -glucan, kelp ⁇ -glucan, thermal gel ⁇ -glucan, golden algae kelp ⁇ -glucan, mushroom ⁇ -glucan, lichen ⁇ -glucan sugar, oyster mushroom ⁇ -glucan, zymosan, black fungus ⁇ -glucan, barley polysaccharide.
  • one or a mixture of ⁇ -glucans from yeast, oat, barley can be used, more preferably, selected from yeast ⁇ -glucan - Glucan and/or oat beta-glucan.
  • raw materials such as plants and fungi containing this component can be used to endow a certain content of ⁇ -glucan in the final composition.
  • active ingredients of ⁇ -glucan extracted from these raw materials with higher purity are directly used.
  • ⁇ -glucan may be used directly to form a mixture, or ⁇ -glucan may be prepared in advance as a solution or emulsion.
  • the dosage ratio of phytosterols to ⁇ -glucans may be below 45:1, preferably 30:1, more preferably below 25:1, most preferably at 20 :1 or less, can be enumerated as (17, 18 or 19): below 1, the ratio of phytosterols is too high, and there is also a concern that the synergistic effect of the two components is not good.
  • the lower limit of the ratio can be more than 0.01:1, preferably more than 0.1:1, more preferably more than 0.5:1, can be enumerated as (0.3, 0.8, 1, 2, 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13, 14 or 15): 1 or more. If the proportion of phytosterols is too low, there is a concern that the synergistic effect of the two components will not be good when the absolute amount of phytosterols is low.
  • the usage amount (especially the highest usage amount) of phytosterol and ⁇ -glucan in the functional composition provided by the present invention is not limited in principle.
  • the content of the phytosterol can be more than 0.1% by mass, preferably 0.15 to 10% by mass, more preferably 0.2 to 6% by mass, further preferably 1 to 5% by mass, more preferably 2 to 5% by mass.
  • the content of the ⁇ -glucan can be more than 0.01% by mass, preferably 0.01-0.2% by mass, more preferably 0.01-0.15%, still more preferably 0.01-0.1%, and still more preferably 0.02-0.02% by mass. 0.08%, more preferably 0.02 to 0.06% by mass. If the content is too low, there may be concerns about poor synergistic effects in some cases, and if the content is too high, there may be concerns about poor safety for the human body.
  • the present invention further found that under the premise of ensuring cell activity, the effect of using phytosterol or ⁇ -glucan alone on regulating blood sugar cannot be said to be obvious, and sometimes it is even opposite. Through the matching of the above contents, even a lower content of phytosterol or a lower content of ⁇ -glucan can show the effect of synergistic control of blood sugar.
  • the functional composition of the present invention includes at least the above-described phytosterols and ⁇ -glucan.
  • the formation method of the composition there is no particular limitation on the formation method of the composition, and it can be formed by mixing the above-mentioned plants, fungi and other substances containing these components, or by mixing two kinds of high-purity extracts.
  • composition of the present invention are not particularly limited, and other edible components, food additives or solvent components commonly used in the art can be used without impairing the effect of the present invention.
  • the functional composition of the present invention may exist in a liquid form, or in a semi-solid or solid form.
  • composition of the present invention has been verified by experiments to improve the phenomenon of reducing glucose intake caused by PA, indicating that the composition can alleviate insulin resistance induced by PA, so it can have a more obvious effect on blood sugar regulation, and also has the effect of improving blood lipids.
  • the effect of improving human immunity therefore, can be used as a functional health care product or functional health care additive.
  • a functional health food is provided, especially a blood sugar control health food suitable for diabetic patients. It is processed through the functional composition described in the first aspect above.
  • the food of the present invention can generally be pasta, beverage, ready-to-drink food, baked cake, sauce or functional nutritional supplement food.
  • For pasta it may include staple foods processed or made from flour raw materials as staple foods, staple foods of miscellaneous grains, etc., specifically steamed buns, cakes, noodles, and stuffed staple foods.
  • baked pastries it can be baked cakes or biscuits etc. mainly based on cream, eggs and baking powder.
  • the beverage is not particularly limited, and may be fruit beverages, vegetable beverages, milk tea beverages, tea beverages, milk, yogurt, vitamin beverages, and the like.
  • fruit or vegetable drinks in addition to the two functional components of the present invention, fruit or vegetable juices, or their solid components, etc. may also be included.
  • vitamin beverages in addition to including the two functional components of the present invention, it also mainly includes functional vitamins and other functional ingredients, specifically white sugar, cyclamate, acesulfame potassium, taurine, etc. acid, potassium sorbate, lysine, inositol, vitamin pp, vitamin B6, vitamin B12, citric acid, etc.
  • the reconstitutable food typically it may be a reconcilable milk powder product, such as adult milk powder, middle-aged and elderly milk powder, and the like.
  • the functional nutritional supplement food can be used as a nutritional supplement or a meal replacement.
  • it in addition to the two functional components of the present invention, it can also include one of the following components: One or more types: protein, fat, essential carbohydrates, dietary fiber, supplementary elements, vitamins, plant or dietary ingredients, etc.
  • the protein is selected from at least one of whey protein powder, soybean protein isolate, whole milk powder, whole egg powder, lactoferrin, bovine colostrum, amino acid, protein peptide; and, the amino acid is selected from L -Lysine-L-glutamic acid, L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine At least one of acid, L-leucine; the protein peptide is selected from soybean oligopeptide, wheat protein peptide, silkworm chrysalis protein peptide, marine fish oligopeptide powder, kola peptide, amino peptide, ovalbumin peptide one or more.
  • the fat can include at least one of saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acid, OPO structural lipid, DHA, EPA, ARA, phospholipid, more specifically the fat includes safflower oil, walnut oil , peanut oil, soybean oil, argan oil, olive oil, tea oil, cane oil, olive oil, coconut oil, perilla oil, deep-sea fish oil, cocoa butter, palm oil, butter, butter, lard, medium chain glycerin Triesters, Lecithin.
  • the carbohydrates include starch or modified starch.
  • the dietary fiber comprises one or more of inulin, konjac flour, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, soybean polysaccharide, cyclodextrin, resistant dextrin and soybean fiber.
  • the supplementary elements are selected from metal ion salts of citric organic acids, such as calcium citrate, L-calcium lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, selenous One or more of sodium gluconate, copper gluconate, chromium sulfate, manganese gluconate and magnesium gluconate.
  • citric organic acids such as calcium citrate, L-calcium lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, selenous One or more of sodium gluconate, copper gluconate, chromium sulfate, manganese gluconate and magnesium gluconate.
  • the vitamins are selected from vitamin A, ⁇ -carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, niacin, choline, inositol, One or more of biotin.
  • the plant or dietary components include one or more of cereals, beans, potatoes, vegetables, fungi and algae, nuts and seeds, fish and shrimp, poultry and livestock meat, and fruits.
  • the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the technical field. ⁇ raw material>
  • the mass parts refer to the mass parts of phytosterols and yeast ⁇ -glucan as active ingredients
  • the The ratio refers to the mass ratio of phytosterol and yeast ⁇ -glucan as active ingredients.
  • Each experimental example was prepared by mixing phytosterol and yeast ⁇ -glucan raw materials according to the components shown in Table 1 below.
  • HepG2 cells were cultured in complete DMEM medium containing 10% FBS at 37°C in a cell culture incubator with 5% CO 2 saturated humidity, and the medium was changed every other day.
  • the confluence in the logarithmic growth phase is greater than 80%, it can be subcultured, washed twice with PBS, digested with 0.25% trypsin for 10-15 minutes, until the cells are detached from the bottle wall, transferred to a centrifuge tube, and blown to a single cell with a sterile needle, at 1: The ratio of 3 was subcultured. Cells in the logarithmic growth phase were used for the experiment.
  • a single cell suspension of HepG2 hepatocytes was prepared, about 1 ⁇ 10 4 cells were seeded in a 96-well plate, cultured until the cells accounted for about 80% of the wells, and drug intervention was performed. After 24 h of drug intervention, 10 ⁇ L of CCK8 solution was added to each well of the plate using a pipette. After incubation for 4 h in a constant temperature incubator at 37 °C, the absorbance at 450 nm was measured using a microplate reader.
  • Drugs intervene the cells for 2 hours in advance, then add 0.2mM palmitate (Palmitate, PA) to treat for 24 hours, absorb the supernatant of the culture medium, and measure the glucose content in the supernatant of the culture medium (Beijing Prelite Glucose Consumption Assay Kit) to reflect the glucose consumption , measured according to the instructions of the kit, and the degree of insulin resistance in the cells is fed back through the glucose consumption. The lower the glucose consumption, the worse the insulin resistance, and the higher the glucose consumption, the weakened insulin resistance.
  • Table 2-4 shows the effect of yeast ⁇ -glucan on the viability of HepG2 cells;
  • Table 2-5 shows the effect of phytosterols on the viability of HepG2 cells.
  • CCK-8 Cell Proliferation Detection Kit is a WST-8 (chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazole monosodium salt) is a rapid and sensitive kit widely used in the detection of cell proliferation and cytotoxicity.
  • WST-8 can be reduced by dehydrogenase in mitochondria to generate highly water-soluble orange-yellow formazan, the color of which is proportional to the proliferation of surviving cells, and Cytotoxicity is inversely proportional.
  • a microplate reader to measure the OD value at a wavelength of 450nm, which can indirectly reflect the number of viable cells. The higher the detected OD value, the greater the number of viable cells, and the lower the OD value, the fewer the number of viable cells.
  • Insulin resistance will lead to a decrease in the rate of glucose consumption by cells, and the degree of cellular insulin resistance can be reflected by detecting the amount of glucose consumption in cells. If glucose consumption is low, the degree of cellular insulin resistance is high, and if glucose consumption is high, the degree of insulin resistance is low.
  • the present invention provides the effect of the phytosterol and yeast ⁇ -glucan composition on hypoglycemia, especially on improving PA-induced insulin resistance, and provides a new idea for the development of future functional foods.
  • Phytosterols and yeast ⁇ -glucan have broad prospects in improving blood sugar in the body.
  • Our research shows that in the in vitro model, insulin resistance has been significantly improved in HepG2 cells treated with the combination of yeast ⁇ -glucan and phytosterol, and there is a good synergistic effect between the components.
  • the modulated milk powder containing phytosterols and yeast ⁇ -glucan is suitable for middle-aged and elderly people. Every 1000 parts of the modulated milk powder is prepared from the following components by weight:
  • the used raw materials of the milk powder of the present invention are: 436 parts of whole milk powder, 8.08 parts of phytosterol esters (phytosterol 99% in each part), 0.51 part of yeast beta glucan (98.0% of yeast beta glucan in each part) , 250 parts of skimmed milk powder, 83.41 parts of lactose, 179 parts of solid corn syrup, 40 parts of isomaltooligosaccharide, 2 parts of compound vitamins, and 1 part of compound minerals; quality, evaporative concentration and spray drying into a powdery semi-finished product, and the evenly mixed milk powder is filled with nitrogen and packaged to obtain the final product.
  • the product contains 0.8% phytosterol and 0.05% yeast ⁇ -glucan, the ratio is 16:1.
  • the modulated milk powder containing phytosterols and yeast ⁇ -glucan is suitable for middle-aged and elderly people. Every 1000 parts of the modulated milk powder is prepared from the following components by weight:
  • the raw materials used in the milk powder of the present invention are: 436 parts of whole milk powder, 12.12 parts of phytosterol esters (99% of phytosterols in each part), 0.26 parts of yeast beta glucan (98.0% of yeast beta glucan in each part) , 250 parts of skimmed milk powder, 79.62 parts of lactose, 179 parts of solid corn syrup, 40 parts of isomalto-oligosaccharide, 2 parts of compound vitamins, and 1 part of compound minerals; quality, evaporative concentration and spray drying into a powdery semi-finished product, and the evenly mixed milk powder is filled with nitrogen and packaged to obtain the final product.
  • the product contains 1.2% phytosterol and 0.025% yeast ⁇ -glucan, the ratio is 48:1.
  • the modulated milk powder containing phytosterols and yeast ⁇ -glucan is suitable for middle-aged and elderly people. Every 1000 parts of the modulated milk powder is prepared from the following components by weight:
  • the used raw materials of the milk powder of the present invention are: 436 parts of whole milk powder, 2.42 parts of phytosterol powder (phytosterol 99% in each part), 0.61 part of yeast beta glucan (98.0% of yeast beta glucan in each part) , 250 parts of skimmed milk powder, 88.97 parts of lactose, 179 parts of solid corn syrup, 40 parts of isomaltooligosaccharide, 2 parts of compound vitamins, and 1 part of compound minerals; quality, evaporative concentration and spray drying into a powdery semi-finished product, and the evenly mixed milk powder is filled with nitrogen and packaged to obtain the final product.
  • the product contains 0.24% phytosterol and 0.06% yeast beta glucan, the ratio is 4:1.
  • Modulated milk containing phytosterols and yeast ⁇ -glucan prepared from the following components by weight per 1000 parts of modulated milk:
  • Modulated milk of the present invention 990.29 parts of raw milk, 0.51 part of yeast beta glucan (98.0% of yeast beta glucan in each part), 0.40 part of phytosterol powder (99% of phytosterol in each part), 8.3 parts of fructooligosaccharides 0.5 part, 0.5 part of mono-diglyceride fatty acid ester; the above raw materials are mixed, homogenized, UHT sterilized, homogenized, and aseptically filled to obtain the final product.
  • the product contains 0.04% phytosterol and 0.05% yeast beta glucan, with a ratio of 0.8:1.
  • Modulated milk containing phytosterols and yeast ⁇ -glucan prepared from the following components by weight per 1000 parts of modulated milk:
  • Modulated milk of the present invention 983.04 parts of raw milk, 0.61 part of yeast beta glucan (98.0% of yeast beta glucan in each part), 0.29 part of phytosterol powder (99% of phytosterol in each part), 15.56 parts of fructooligosaccharides 0.5 part, 0.5 part of mono-diglyceride fatty acid ester; the above raw materials are mixed, homogenized, UHT sterilized, homogenized, and aseptically filled to obtain the final product.
  • the phytosterol content in the product is 0.029%, the content of yeast ⁇ -glucan is 0.06%, and the ratio is 0.48:1.
  • Modulated milk containing phytosterols and yeast ⁇ -glucan suitable for middle-aged and elderly people, prepared from the following components in parts by weight per 1000 parts of modified milk:
  • the used raw materials of the milk powder of the present invention are: 436 parts of whole milk powder, 12.12 parts of phytosterol powder (phytosterol 99% in each part), 0.51 part of yeast beta glucan (98.0% of yeast beta glucan in each part) , 250 parts of skimmed milk powder, 79.37 parts of lactose, 179 parts of solid corn syrup, 40 parts of isomaltooligosaccharide, 2 parts of compound vitamins, and 1 part of compound minerals; quality, evaporative concentration and spray drying into a powdery semi-finished product, and the evenly mixed milk powder is filled with nitrogen and packaged to obtain the final product.
  • the product contains 1.2% phytosterol and 0.05% yeast beta glucan, the ratio is 24:1.
  • the functional composition provided by the invention can be prepared industrially and is suitable for regulating blood sugar.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition nutritive fonctionnelle, en particulier une composition hypoglycémiante. La composition comprend : i) un ou plusieurs phytostérols ; et ii) des bêta-glucanes provenant d'une ou de plusieurs sources, le rapport entre la teneur en phytostérols et celle en bêta-glucanes étant inférieur à 45 : 1 dans la composition.
PCT/CN2022/137829 2021-12-10 2022-12-09 Composition hypoglycémiante WO2023104181A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111504887.4A CN114145457A (zh) 2021-12-10 2021-12-10 降血糖组合物
CN202111504887.4 2021-12-10

Publications (1)

Publication Number Publication Date
WO2023104181A1 true WO2023104181A1 (fr) 2023-06-15

Family

ID=80454165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/137829 WO2023104181A1 (fr) 2021-12-10 2022-12-09 Composition hypoglycémiante

Country Status (3)

Country Link
CN (1) CN114145457A (fr)
CA (1) CA3183772A1 (fr)
WO (1) WO2023104181A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114145457A (zh) * 2021-12-10 2022-03-08 黑龙江飞鹤乳业有限公司 降血糖组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102907606A (zh) * 2012-11-16 2013-02-06 西藏天麦力健康品有限公司 一种β-葡聚糖组合物及其应用
CN105394182A (zh) * 2015-10-27 2016-03-16 江西美庐乳业集团有限公司 一种具有降血糖功效及促进心脑血管健康的营养包
CN106579393A (zh) * 2016-12-23 2017-04-26 上海奥医生物医药科技有限公司 一种糖尿病专用型临床营养配方及其制备方法
CN113693131A (zh) * 2021-08-19 2021-11-26 呼伦贝尔蒙源乳业有限公司 一种益生菌富硒高钙中老年配方奶粉
CN114145457A (zh) * 2021-12-10 2022-03-08 黑龙江飞鹤乳业有限公司 降血糖组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010780A0 (fi) * 2001-04-12 2001-04-12 Raisio Benecol Oy Parannetut koostumukset
US8084065B2 (en) * 2006-05-29 2011-12-27 Fenchem Enterprises, Ltd Compositions for treating and preventing hyperlipidemia
CN101999430A (zh) * 2010-11-10 2011-04-06 西藏天麦力健康品有限公司 一种具有降糖、降脂功能的饼干
CN106617072A (zh) * 2016-12-20 2017-05-10 广州莱可福生物科技有限公司 一种植物甾醇复合降脂组方及其片剂制备方法
CN111214642A (zh) * 2018-11-23 2020-06-02 河南旭仁堂生物科技有限公司 一种疏通微循环的中药组合物
CN110122724A (zh) * 2019-05-27 2019-08-16 九饮堂生物科技有限公司 一种具有保健功效的固体饮料及其制备方法
CN111407685A (zh) * 2020-04-29 2020-07-14 苏州美尚洁生物科技有限公司 重组纤连-类人胶原蛋白抗衰组合物及其制备方法
CN113575928A (zh) * 2020-04-30 2021-11-02 北京曜食同源商贸有限公司 富含植物多酚和甾醇的健康食品组合物
CN113730547A (zh) * 2021-09-17 2021-12-03 江苏协合转化医学研究院有限公司 一种降脂、溶解血栓组合物及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102907606A (zh) * 2012-11-16 2013-02-06 西藏天麦力健康品有限公司 一种β-葡聚糖组合物及其应用
CN105394182A (zh) * 2015-10-27 2016-03-16 江西美庐乳业集团有限公司 一种具有降血糖功效及促进心脑血管健康的营养包
CN106579393A (zh) * 2016-12-23 2017-04-26 上海奥医生物医药科技有限公司 一种糖尿病专用型临床营养配方及其制备方法
CN113693131A (zh) * 2021-08-19 2021-11-26 呼伦贝尔蒙源乳业有限公司 一种益生菌富硒高钙中老年配方奶粉
CN114145457A (zh) * 2021-12-10 2022-03-08 黑龙江飞鹤乳业有限公司 降血糖组合物

Also Published As

Publication number Publication date
CA3183772A1 (fr) 2023-06-10
CN114145457A (zh) 2022-03-08

Similar Documents

Publication Publication Date Title
US8828472B2 (en) Food products containing omega-3 fatty acids
EP3484311B1 (fr) Compositions utilisées pour la mise en oeuvre de méthodes pour la gestion de troubles digestifs
US20090297618A1 (en) Composition beneficial for visuognosis persistence and use thereof
KR20150018784A (ko) 샤도네이씨 생성물의 치료용도
JP2008174539A (ja) 紫色の馬鈴薯を使用した肥満患者用の健康機能食品
CN114128890A (zh) 营养补充性组合物
WO2023104181A1 (fr) Composition hypoglycémiante
CN112056402A (zh) 一种具有辅助降血糖功能的调制骆驼乳粉
CN115736256A (zh) 辅助保护骨关节的功能性组合物
CN116076728B (zh) 促进双歧杆菌生长的组合物
US20200060323A1 (en) Pgc-1 alpha protein expression promoter and slow-to-fast muscle conversion inhibitor
EP2852298B1 (fr) Composition pour prise en charge du diabète ou du pré-diabète
CN114304651A (zh) 提高免疫力组合物
JP7396798B2 (ja) 腸内酪酸産生促進用組成物
CN107712875A (zh) 黑藜麦减肥代餐
DK2865278T3 (en) Binder fat obtained from biomass, derived from beer production
CN116420875B (zh) 辅助血脂调节和心脑血管健康的营养组合物
JP2018050488A (ja) 免疫賦活用組成物
CN112715941B (zh) 一种能够减肥及增强免疫力的组合物、制品及其应用
WO2022091736A1 (fr) Composition pour amélioration de la flore bactérienne intestinale, et composition pour inhibition de la production de matière putréfiée intestinale
KR20120040890A (ko) 상황버섯균사체 발효 블루베리 추출물의 비만 억제 또는 치료 용도
JP5870181B1 (ja) 血清コレステロール値及び／又は血中脂質値の改善剤
JP2014529596A (ja) 食事を変換する方法
CN115956681A (zh) 辅助保护骨关节营养组合物
JP2020068718A (ja) 血中コレステロール低減用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22903598

Country of ref document: EP

Kind code of ref document: A1